Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Flu drug safety under spotlight

  • Comment
Drug regulators have recommended updated product information for the anti-flu drug oseltamivir (Tamiflu).

Drug regulators have recommended updated product information for the anti-flu drug oseltamivir (Tamiflu).

The European Medicines Agency said it had been made aware of reports of neuro-psychiatric adverse events linked with oseltamivir use in Japan.

The agency's recommended wording states: 'Convulsion, depressed level of consciousness, abnormal behaviour, hallucinations and delirium have been reported during Tamiflu administration, leading in rare cases to accidental injury.

'Patients, especially children and adolescents should be closely monitored and their healthcare professional should be contacted immediately if the patient shows any signs of unusual behaviour.'

www.emea.eu.int

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.